The company's financial position is strained by a negative equity balance of -$265.6 million and a total debt load that has increased to $230.9 million as of 2026Q1.
Karyopharm Therapeutics Inc. (KPTI) balance sheet — 15-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Total Current Assets | 106.38M | 103.15M | 156.49M | 233.92M | 350.16M | 275.61M | 276.53M | 278.57M | 334.61M | 148.42M | 131.64M | 177.6M | 207.75M | 157.96M | 954K | 6.87M |
| Cash & Short-Term Investments | 65.11M | 63.74M | 108.71M | 191.44M | 277.97M | 228.62M | 249.24M | 261.96M | 328.2M | 146.47M | 129.55M | 175.63M | 205.72M | 155.97M | 391K | 6.51M |
| Cash Only | 54.98M | 60.54M | 62.48M | 52.23M | 135.19M | 190.46M | 85.92M | 128.86M | 118.02M | 69M | 49.66M | 58.36M | 150.61M | 155.97M | 391K | 6.51M |
| Short-Term Investments | 10.13M | 3.2M | 46.24M | 139.21M | 142.78M | 38.16M | 163.32M | 133.1M | 210.18M | 77.47M | 79.89M | 117.28M | 55.12M | 0 | 0 | 0 |
| Accounts Receivable | 29.87M | 26.18M | 30.77M | 26.96M | 47.09M | 22.5M | 12.88M | 7.86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 69.26 | 65.42 | 77.32 | 67.39 | 109.42 | 39.14 | 43.5 | 70.17 | - | - | - | - | - | - | - | - |
| Inventory | 3.99M | 4.04M | 4.74M | 3.04M | 4.22M | 4.11M | 2.64M | 346K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 235.67 | 247.75 | 287.95 | 224.75 | 295.75 | 440.53 | 356.77 | 52.47 | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 9.19M | 12.28M | 12.47M | 20.89M | 6.35M | 2.48M | 1.12M | 0 | 200K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 4.94M | 5.27M | 7.93M | 6.52M | 8.01M | 29.7M | 36.52M | 16.39M | 6.58M | 31.87M | 48.75M | 37.84M | 12.59M | 270K | 357K | 358K |
| Property, Plant & Equipment | 4.35M | 4.65M | 6.28M | 4.88M | 7.38M | 9.56M | 11.58M | 13.66M | 3.86M | 2.19M | 2.84M | 3.48M | 2.75M | 240K | 327K | 328K |
| Fixed Asset Turnover | 32.03x | 31.40x | 23.11x | 29.91x | 21.29x | 21.95x | 9.33x | 2.99x | 7.85x | 0.73x | 0.05x | 0.07x | 0.08x | 1.61x | 1.94x | 0.46x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.02M | 351K | 0 | 0 | 0 | 0 | 24.21M | 2.02M | 2M | 29.4M | 45.43M | 33.88M | 8.66M | 0 | 0 | 0 |
| Other Non-Current Assets | 585K | 267K | 1.64M | 1.64M | 633K | 20.14M | 722K | 714K | 716K | 290K | 479K | 482K | 1.17M | 30K | 30K | 30K |
| Total Assets | 111.32M | 108.42M | 164.42M | 240.44M | 358.17M | 305.31M | 313.05M | 294.96M | 341.19M | 180.29M | 180.38M | 215.44M | 220.34M | 158.23M | 1.31M | 7.22M |
| Asset Turnover | 1.31x | 1.35x | 0.88x | 0.61x | 0.44x | 0.69x | 0.35x | 0.14x | 0.09x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.48x | 0.02x |
| Asset Growth % | -74.23% | -34.06% | -31.62% | -32.87% | 17.32% | -2.47% | 6.13% | -13.55% | 89.24% | -0.05% | -16.27% | -2.22% | 39.25% | 11969.11% | -81.85% | - |
| Total Current Liabilities | 134.23M | 92.06M | 92.26M | 69.48M | 65.91M | 73.72M | 60.2M | 46.35M | 46.9M | 49.47M | 16.48M | 15.13M | 12.3M | 3.29M | 1.93M | 2.12M |
| Accounts Payable | 7.66M | 4M | 5.11M | 3.12M | 2.77M | 1.6M | 4.45M | 985K | 4.33M | 5.67M | 4.75M | 3.81M | 6.29M | 1.74M | 1.08M | 1.14M |
| Days Payables Outstanding | 322.36 | 245.6 | 310.31 | 230.65 | 194.16 | 171.99 | 600.46 | 149.37 | 9.8 | 19.28 | 19.95 | 14.22 | 38.17 | 22.32 | 27.86 | - |
| Short-Term Debt | 0 | 21.01M | 24.43M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 297K | 2.34M | 9.36M | 21.92M | 0 | 0 | 0 | 79K | 66K | 200K |
| Other Current Liabilities | 46.7M | 5.96M | 15.56M | 18.16M | 21.47M | 20.36M | 609K | 500K | 717K | 436K | 363K | 301K | 188K | 305K | 24K | 16K |
| Current Ratio | 0.79x | 1.12x | 1.70x | 3.37x | 5.31x | 3.74x | 4.59x | 6.01x | 7.13x | 3.00x | 7.99x | 11.74x | 16.89x | 47.98x | 0.49x | 3.24x |
| Quick Ratio | 0.76x | 1.08x | 1.64x | 3.32x | 5.25x | 3.68x | 4.55x | 6.00x | 7.13x | 3.00x | 7.99x | 11.74x | 16.89x | 47.98x | 0.49x | 3.24x |
| Cash Conversion Cycle | -17.43 | 67.56 | 54.96 | 61.48 | 211.01 | 307.68 | -200.19 | -26.72 | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 307.25M | 309.28M | 258.17M | 307.17M | 308.92M | 311.26M | 202.3M | 198.84M | 111.12M | 1.36M | 1.67M | 1.95M | 1.24M | 0 | 27.26M | 17.76M |
| Long-Term Debt | 209.63M | 205.88M | 162.95M | 170.92M | 170.1M | 169.29M | 117.93M | 109.86M | 102.66M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 22.4M | 5.74M | 6.71M | 2.79M | 6.1M | 8.97M | 11.29M | 13.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 92.44M | 25.32M | 88.51M | 133.46M | 132.72M | 133M | 73.09M | 73.59M | 3.92M | 1.36M | 1.67M | 1.95M | 1.24M | 0 | 27.26M | 17.76M |
| Total Liabilities | 441.49M | 401.34M | 350.44M | 376.64M | 374.83M | 384.98M | 262.5M | 245.19M | 158.02M | 50.83M | 18.14M | 17.08M | 13.54M | 3.29M | 29.19M | 19.88M |
| Total Debt | 215.88M | 233.61M | 194.52M | 177.02M | 179.07M | 180.58M | 131.13M | 124.7M | 102.66M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | 160.91M | 173.07M | 132.05M | 124.78M | 43.89M | -9.88M | 45.21M | -4.15M | -15.36M | -69M | -49.66M | -58.36M | -150.61M | -155.97M | -391K | -6.51M |
| Debt / Equity | -0.65x | - | - | - | - | - | 2.59x | 2.51x | 0.56x | - | - | - | - | - | - | - |
| Debt / EBITDA | -2.63x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -1.96x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -3.57x | -3.27x | -1.04x | -4.99x | -5.60x | -3.75x | -6.22x | -11.75x | -70.55x | - | - | - | -75776.00x | - | - | - |
| Total Equity | -330.17M | -292.93M | -186.02M | -136.21M | -16.66M | -79.67M | 50.55M | 49.77M | 183.17M | 129.46M | 162.24M | 198.37M | 206.79M | 154.93M | -27.88M | -12.65M |
| Equity Growth % | -193.35% | -57.47% | -36.57% | -717.76% | 79.09% | -257.62% | 1.55% | -72.83% | 41.48% | -20.2% | -18.21% | -4.08% | 33.47% | 655.78% | -120.35% | - |
| Book Value per Share | -11.41 | -26.79 | -22.90 | -17.89 | -3.05 | -15.89 | 10.52 | 12.05 | 48.37 | 42.31 | 64.86 | 83.54 | 99.63 | 383.02 | -14.06 | -6.38 |
| Total Shareholders' Equity | -330.17M | -292.93M | -186.02M | -136.21M | -16.66M | -79.67M | 50.55M | 49.77M | 183.17M | 129.46M | 162.24M | 198.37M | 206.79M | 154.93M | -27.88M | -12.65M |
| Common Stock | 14K | 14K | 13K | 12K | 12K | 8K | 7K | 7K | 6K | 5K | 4K | 4K | 3K | 3K | 0 | 0 |
| Retained Earnings | -1.85B | -1.76B | -1.56B | -1.49B | -1.34B | -1.18B | -1.07B | -873.34M | -673.75M | -495.34M | -366.1M | -256.53M | -138.35M | -62.57M | -28.62M | -12.73M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 41K | 71K | -356K | -161K | -638K | 191K | 518K | -37K | -244K | -217K | -274K | -282K | -29K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying KPTI stock.
As of 2025, Karyopharm Therapeutics Inc. (KPTI) had total assets of $108.4M including $103.1M in current assets.
Karyopharm Therapeutics Inc. (KPTI) carries total debt of $233.6M, offset by $63.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Karyopharm Therapeutics Inc. (KPTI) has total shareholders' equity (book value) of $-292.9M ($-26.79 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Karyopharm Therapeutics Inc. (KPTI) reported a current ratio of 1.12x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Liquidity and dilution risk
Metrics are mathematically derived from official filings.
Balance Sheet Erosion Accelerates Downward
As reported in recent financial filings, Karyopharm's total assets have declined from $240.4 million in 2023Q4 to $131.4 million in 2026Q1, reflecting a persistent erosion of the company's resource base as it struggles to fund ongoing operations through its existing capital structure.
The consistent contraction in total assets, coupled with a deepening deficit in retained earnings, suggests that the company is consuming its capital base to sustain commercialization efforts. This trajectory indicates that the current business model is not generating sufficient internal value to replenish the balance sheet, leaving the firm increasingly reliant on external financing.
Leverage Burden Constrains Financial Flexibility
Based on the company's reported figures, total debt has risen from $177.0 million in 2023Q4 to $230.9 million in 2026Q1, creating a significant liability overhang that complicates the firm's ability to navigate its current negative equity position.
The increase in debt levels relative to a shrinking asset base suggests that the company is utilizing leverage to bridge its operational funding gap. Investors should monitor the maturity profile of these obligations, as the lack of positive equity indicates that the company is effectively operating on borrowed time and capital.
Liquidity Buffer Nearing Critical Thresholds
According to recent SEC filings, Karyopharm's cash position of $60.5 million as of 2025Q4, when viewed against its current ratio of 1.12, suggests a narrowing margin of safety for meeting short-term obligations in the face of ongoing operational cash burn.
The decline in the current ratio from 3.37 in 2023Q4 to 1.12 in 2025Q4 highlights a rapid deterioration in liquidity, which may limit the company's operational agility. This trend warrants further investigation into the company's ability to maintain sufficient working capital without resorting to dilutive equity raises.
Negative Equity Obscures Solvency Risks
Analysis of the balance sheet reveals a persistent negative equity position, which reached -$265.6 million in 2026Q1, indicating that the company's accumulated losses have completely eroded the book value of shareholder capital over the observed period.
This negative equity status is a non-obvious risk factor that suggests the company is technically insolvent on a book-value basis, relying entirely on the market's willingness to provide future funding. Such a structure makes the firm highly sensitive to any disruption in capital markets or failure to meet clinical milestones.